1x ARK Genomic Tracker
NAV as of 21 Oct 2026, 12:00 AM UTC
$4.06 (2.53%)
Year-To-Date Change
71.59%
-
LSE
-
XAMS
-
Xetra
Capital at risk. NAV calculated by Leverage Shares. For more information on the calculation please click here These products are offered by Leverage Shares, and are not offered, endorsed or approved by Ark Investment Management.
Overview
What is the 1x ARK Genomic Tracker ETP?
The LS ARK Genomic Revolution Tracker ETP (ISIN XS2399368062) is an exchange traded product (ETP) that seeks to deliver the daily performance of ARK Genomic Revolution ETF. It has physical ownership of the underlying, so it does not use swaps or other derivatives to achieve its exposure, and it does not have credit risk. It does not use leverage, so it is not subject to volatility decay. You cannot lose more than the amount you invest. The LS ARK Genomic Revolution Tracker ETP has an annual management fee of 0.35% and is listed on the following exchanges: London Stock Exchange, Euronext Amsterdam, Deutsche Börse Xetra. It can be held over longer periods as well as traded intraday.
ETP objective
To seek daily investment results, before fees and expenses, that correspond to 100% (1x) the daily performance of the underlying stock (ARKG).
Who is this product for?
Investors and traders seeking to express long-term bullish views or tactically trade positions, via physical ownership and without a leverage component.
*However, these are complex products.
Value of Underlying Assets
$1,337,276
or 26,826 shares of ARKG
AUM
$1,337,249
or 329,747 shares of 1ARG
Liabilities
$27
Listings & Tickers
Key Facts
Net Asset Value
- NAV (as of 21 Oct 2026)
- $4.06
- Daily Return (% NAV change)
- 2.53%
- Daily Change (of NAV)
- $0.10
Structure
- Structure
- ETP
- Domicile
- Ireland
- Replication Method
- Physical
- Dividends
- Reinvested
- Underlying Asset
- ARKG
- Target Weights
- Rebalance Frequency
Fees
- Annual Management Fee
- 0.35%
- Interest Paid On Cash Balances
- Performance Fee
- Stock Borrow Rate
Tax & Legal
- ISA
- Eligible
- SIPP
- Eligible
- UK Fund Reporting Status
- Yes (effective 13/12/2021)
- US IRS Sec 871(m)
- Not applicable
Passported Countries:
United Kingdom
Italy
Germany
France
Spain
Netherlands
Ireland
Poland
Belgium
Sweden
Norway
Austria
* The information on this website regarding UK Fund Reporting Status is accurate as of the stated effective date (the "Effective Date"). Leverage Shares makes no representation or warranty that such information will remain accurate, complete or current thereafter, assumes no obligation to update it, and, to the fullest extent permitted by applicable law, accepts no responsibility or liability for any inaccuracies or omissions arising after the Effective Date.
Key Services Providers
- Issuer
- Leverage Shares plc
- Arranger
- Leverage Shares Management Company Limited
- Trustee
- Apex Corporate Trustees (UK) Limited
- Issuing and Paying Agent
- U.S. Bank Europe DAC
- Registrar
- U.S. Bank Europe DAC
- Portfolio Administrators
- Flexinvest Limited
- Stock Borrowing Provider and Custodian
- Interactive Brokers LLC, Morgan Stanley & Co. LLC and/or Pershing LLC
- Determination Agent
- Calculation Agent Services LLC
- Initial Authorised Participant
- BNP Paribas Arbitrage S.N.C.,Virtu Financial Ireland Limited, Flow Traders and others
- Sponsor
Frequently Asked Questions about the LS ARK Genomic Revolution Tracker ETP
- London Stock Exchange: 1ARG (USD), ARKC (GBP)
- Euronext Amsterdam: 1ARKG (EUR)
- Deutsche Börse Xetra: ARG1 (EUR)
